Here we provide you with sections from our open access annual reports, which are directed at public health practitioners, policies makers, doctors, researchers and the general public.
The objective of these reports is to present the key aspects of our work in an accessible, summarized format. The majority of the work presented has been published in peer-reviewed publications and can be seen in the publications section of krisp.org.za.
Authors: SATuRN / Life Technologies
Introduction:Antiretroviral (ARV) drugs are becoming increasingly available to treat HIV-1 infected individuals in the developing world. The goal of many governments and non-governmental organizations is to sustain the effective ARV treatment of > 5 million people in Africa. Pharmaceutical companies are reducing both prices and international trade restrictions on patented drugs to allow more equitable access to essential medicines for AIDS, TB and Malaria. However, the widespread increase of treatment is threatened by the appearance of drug resistance.
Public health and patient benefit may be limited by the increase in selection and transmission of broadly ARV resistant viruses. Drug resistance viruses can currently be identified with genetic sequencing of two HIV-1 genes. However, the price of an individual test using commercial methods (ZAR 2,500 or US$ 300) makes it too expensive for public health implementation in southern Africa.
SATuRN HIV Resistance Genotyping:We have developed an in-house HIV resistance genotyping system in collaboration with the Stanford HIV Drug Resistance Database team and it has been internationally validated by the French AIDS Research (French acronym: ANRS).